

mIgG1
BBK2-mIgG1 EC50 = 35 pM
gMFI
2500
2000
1500
1000
500
0
10-12
10-11
10-10
10-9
10-8
10-7
CONCENTRATION LOG [M]

FIG. 1A




FIG. 1B



hIgG-AMANITIN
CD137-AMANITIN
ANTI-Tcell-AMANITIN
#VIABLE ACTIVATED CELLS
10000
8000
6000
4000
2000
0
0.001
0.01
0.1
1
10
100
ADC CONCENTRATION (nM)

FIG. 2A



hIgG-AMANITIN
CD137-AMANITIN
ANTI-Tcell-AMANITIN
#VIABLE NON-ACTIVATED CELLS
1000
800
600
400
200
0
0.001
0.01
0.1
1
10
100
ADC CONCENTRATION (nM)

FIG. 2B



100
80
60
40
20
0
PERCENT SURVIVAL
0
20
40
60
80
DAYS POST TRANSPLANT
PBS
CD137 NAKED
ISOTYPE-AMANITIN
CD137-AMANITIN

FIG. 3



5000
4000
3000
2000
1000
0
#HUMAN T CELLS IN PERIPHERAL BLOOD
0
20
40
60
80
DAYS POST TRANSPLANT
PBS
CD137 NAKED
ISOTYPE-AMANITIN
CD137-AMANITIN

FIG. 4



DAY 0
DAY 5
DAY 9
DAY 14
DAY 22
DAY 27
ENGRAFTMENT CHANGE NORMALIZED
CD137 AMANITIN
ANTI-Tcell AMANITIN
ISOTYPE AMANINTIN
CD137 BBK2
PBS
300
200
100
0
ENGRAFTMENT NORMALIZED TO BASELINE

FIG. 5A



DAY 0
DAY 5
DAY 9
DAY 14
DAY 22
DAY 27
T CELL CHANGE NORMALIZED
CD137 AMANITIN
ANTI-Tcell AMANITIN
ISOTYPE AMANITIN
CD137 BBK2
PBS
140
120
100
80
60
40
20
0
T CELL FREQUENCY
NORMALIZED TO BASELINE

FIG. 5B